Home/Pipeline/Sarclisa (Isatuximab) SC

Sarclisa (Isatuximab) SC

Multiple Myeloma

Regulatory (EU)ActiveN/A

Key Facts

Indication

Multiple Myeloma

Phase

Regulatory (EU)

Status

Active

Company

Sanofi

About Sanofi

Sanofi is a global biopharmaceutical leader with a mission to 'chase the miracles of science' by developing innovative medicines and vaccines. The company has strategically pivoted to become an R&D-driven, AI-powered organization, focusing its deep immunoscience expertise on high-growth areas like immunology and oncology. Its strategy is centered on accelerating drug discovery, optimizing its robust pipeline, and delivering compelling growth through breakthrough therapeutics.

View full company profile

Therapeutic Areas

Immunology Oncology Rare Diseases Neurology Vaccines

Other Multiple Myeloma Drugs

Drug	Company	Phase	Status
PRG1801 (Anti-BCMA CAR-T)	Pregene Biopharma	Phase 1	Active
CAR-NK Therapy	Pregene Biopharma	Phase 1	Active (recruiting)
Tasquinimod	Active Biotech	Preclinical	Active (Academic Partnership)
BCMA CAR-T	Simnova Biotherapeutics	Phase 1	Active
BCMA panCAR (via Orna partnership)	Simnova Biotherapeutics	Preclinical	Active
Measovir®-based candidate	Oncovita	Pre-clinical	Preclinical activity demonstrated
Kyprolis® (carfilzomib)	Cleo Life Sciences	Approved	Supported late-stage development & NDA
inobrodib (CCS1477)	CellCentric	Phase 1/2	Active
ISB 2001	Ichnos Glenmark Innovation	Phase 1b	Active
In Vivo Cell Therapy	GigaMune	Pre-clinical	Active
Hemady	Dexcel Pharma USA	Approved	Commercial
AV-353	AVEO Oncology	Pre-clinical	Active